Zoledronic Acid + Placebo

Phase 2UNKNOWN

0 views this week 0 watching💤 Quiet

Interest: 31/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Osteonecrosis

Conditions

Osteonecrosis

Trial Timeline

Aug 1, 2009 → Dec 1, 2013

NCT ID

NCT00781261

About Zoledronic Acid + Placebo

Zoledronic Acid + Placebo is a phase 2 stage product being developed by Novartis for Osteonecrosis. The current trial status is unknown. This product is registered under clinical trial identifier NCT00781261. Target conditions include Osteonecrosis.

What happened to similar drugs?

1 of 2 similar drugs in Osteonecrosis were approved

Approved (1) Terminated (0) Active (1)

✅AlendronateMerckApproved

🔄Ixmyelocel-TVericelPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (12)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01788176	Phase 2	UNKNOWN	Dec 1, 2013	Dec 1, 2016	Complex Regional Pain Syndromes
NCT01702415	Approved	Withdrawn	Oct 1, 2013	Dec 1, 2015	Cystic Fibrosis
NCT01166178	Phase 3	Terminated	Oct 1, 2010	Jun 1, 2012	Osteoporosis
NCT00844480	Phase 2	Terminated	Mar 1, 2010	Jan 1, 2016	Bone Loss
NCT01016093	Phase 2/3	UNKNOWN	Nov 1, 2009	Dec 1, 2011	Beta-Thalassemia
NCT00781261	Phase 2	UNKNOWN	Aug 1, 2009	Dec 1, 2013	Osteonecrosis
NCT00799266	Phase 3	Completed	Dec 4, 2008	Mar 5, 2018	Osteoporosis
NCT00333229	Approved	Terminated	Mar 1, 2006	Dec 1, 2013	Primary Hormone Receptor Negative Breast Cancer in Premenopausal Women
NCT00320710	Phase 3	Completed	Feb 1, 2006	Jul 1, 2013	Breast Cancer
NCT00375505	Phase 3	Completed	Oct 1, 2005	May 1, 2014	Breast Cancer
NCT00145327	Phase 3	Completed	May 1, 2005	Nov 1, 2009	Osteoporosis
NCT00132808	Phase 3	Completed	Jul 1, 2004	Feb 1, 2008	Osteopenia

Competing Products

3 competing products in Osteonecrosis

See all competitors

Product	Company	Stage	Hype Score
Alendronate	Merck	Approved	39
Zoledronic acid	Novartis	Phase 2	27
Ixmyelocel-T	Vericel	Phase 3	34